{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:47:01Z","timestamp":1794584821477,"version":"4.9.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"41","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,1]]},"DOI":"10.1093\/eurheartj\/ehx175","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T16:41:00Z","timestamp":1490114460000},"page":"3070-3078","source":"Crossref","is-referenced-by-count":363,"title":["Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study"],"prefix":"10.1093","volume":"38","author":[{"given":"Thomas","family":"Cuisset","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Deharo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Quilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Deffarges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Bassez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fourcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"Mouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Emmanuel","family":"Morange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christine","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Louis","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,16]]},"reference":[{"key":"key\n\t\t\t\t20171101055504_ehx175-B1","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B3","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"TRITON-TIMI 38 Investigators","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B4","first-page":"1045","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"36","author":"PLATO Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B5","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","article-title":"Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis","volume":"51","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B6","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"32","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B7","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","year":"1987","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B9","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Academic Research Consortium","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B10","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B11","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1161\/CIRCULATIONAHA.108.833665","article-title":"Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction","volume":"119","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B12","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2007.02.027","article-title":"Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial","volume":"49","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B13","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B14","doi-asserted-by":"crossref","first-page":"9C","DOI":"10.1016\/j.amjcard.2009.06.020","article-title":"Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST segment elevation myocardial infarction","volume":"104","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B15","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.amjcard.2007.06.026","article-title":"Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 Trial","volume":"100","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B16","first-page":"961","article-title":"Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study","volume":"38","author":"LEADERS FREE Investigators","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCGENETICS.110.958561","article-title":"First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET\/OFFSET and RESPOND genotype studies","volume":"3","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcin.2012.09.012","article-title":"Switching acute coronary syndrome patients from prasugrel to clopidogrel","volume":"6","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.114.001555","article-title":"In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry","volume":"7","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3109\/09537104.2015.1119815","article-title":"Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry","volume":"27","year":"2016","journal-title":"Platelets"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCOUTCOMES.114.001223","article-title":"Early medication nonadherence after acute myocardial infarction: insights into actionable opportunities from the TReatment with ADP receptor iNhibitorS: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study","volume":"8","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamacardio.2016.1017","article-title":"Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial","volume":"1","year":"2016","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B23","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/CIRCULATIONAHA.109.904003","article-title":"Medication adherence in cardiovascular disease","volume":"121","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ijcard.2013.12.194","article-title":"Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome","volume":"172","year":"2014","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B25","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2015.04.017","article-title":"Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"65","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20171101055504_ehx175-B26","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/eurheartj\/ehu161","article-title":"Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial","volume":"35","year":"2014","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/41\/3070\/21488287\/ehx175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T09:55:15Z","timestamp":1509530115000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/eurheartj\/article\/38\/41\/3070\/3827697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,16]]},"references-count":26,"journal-issue":{"issue":"41","published-online":{"date-parts":[[2017,5,16]]},"published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx175","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,11,1]]},"published":{"date-parts":[[2017,5,16]]}}}